NASDAQ · CODX
Healthcare · Medical - Devices
$0.94
Down-$0.20 (-17.47%)
Updated Sep 17, 2026, 5:17 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CODX closed at $0.94 after 20 trading sessions, down 14.47% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $1.10 | $1.10 | $0.93 | $0.9408 | 1.54M |
| Sep 15, 2026 | $1.11 | $1.16 | $1.11 | $1.14 | 210.4K |
| Sep 14, 2026 | $1.14 | $1.1696 | $1.11 | $1.11 | 104.13K |
| Sep 11, 2026 | $1.18 | $1.25 | $1.11 | $1.12 | 280.42K |
| Sep 10, 2026 | $1.12 | $1.12 | $1.09 | $1.10 | 85.89K |
| Sep 9, 2026 | $1.14 | $1.15 | $1.10 | $1.12 | 118.46K |
| Sep 8, 2026 | $1.14 | $1.1896 | $1.12 | $1.12 | 85.84K |
| Sep 4, 2026 | $1.18 | $1.1899 | $1.1408 | $1.16 | 60.81K |
| Sep 3, 2026 | $1.18 | $1.1969 | $1.12 | $1.16 | 99.69K |
| Sep 2, 2026 | $1.19 | $1.22 | $1.14 | $1.16 | 70.5K |
| Sep 1, 2026 | $1.23 | $1.23 | $1.15 | $1.19 | 194.67K |
| Aug 31, 2026 | $1.21 | $1.2718 | $1.20 | $1.24 | 70.14K |
| Aug 28, 2026 | $1.26 | $1.285 | $1.18 | $1.21 | 158.13K |
| Aug 27, 2026 | $1.25 | $1.285 | $1.22 | $1.26 | 119.06K |
| Aug 26, 2026 | $1.23 | $1.27 | $1.215 | $1.25 | 79.29K |
| Aug 25, 2026 | $1.24 | $1.30 | $1.22 | $1.23 | 171.01K |
| Aug 24, 2026 | $1.30 | $1.3099 | $1.20 | $1.22 | 326.55K |
| Aug 21, 2026 | $1.18 | $1.23 | $1.13 | $1.21 | 293.3K |
| Aug 20, 2026 | $1.13 | $1.16 | $1.08 | $1.15 | 329.35K |
| Aug 19, 2026 | $1.31 | $1.33 | $0.9396 | $1.10 | 1.79M |
The latest Smart Investors Daily articles mentioning CODX.
CODX research
Company profile and research snapshot.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 23, 2026 | Maxim Group | Hold | — |
| Nov 26, 2025 | Maxim Group | Buy | — |
| Nov 24, 2025 | HC Wainwright & Co. | Neutral | — |
| Oct 28, 2025 | D. Boral Capital | Buy | — |
| Oct 16, 2025 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 10, 2026
Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that on March 9, 2026,
prnewswire.com · Dec 9, 2025
SALT LAKE CITY , Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company is delivering a presentation at the Point-of-Care Testing 2025 Exhibition and Conference in Boston, MA. The presentation, titled "Exploring the Promise of Portable, Cloud-Connected PCR Diagnostics," will unpack Co-Dx's move to portable PCR diagnostics to address evolving point-of-care needs, introduce the Company's upcoming Co-Dx PCR platform* and intuitive smartphone interface, and discuss how Co-Dx is harnessing AI to minimize user error and improve outcomes in real-time point-of-care testing.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CODX.
